Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2B, Partially Blinded, Randomized Study in Treatment Naive HCV [hepatitis C virus] G1 to Compare the Efficacy, Safety, and Tolerability of Three Doses of Locteron [interferon alpha-2b] Plus Ribavirin Given Bi-Weekly in Comparison With PEG-Intron [peginterferon-alfa-2B] Plus Ribavirin Given Weekly.

X
Trial Profile

Phase 2B, Partially Blinded, Randomized Study in Treatment Naive HCV [hepatitis C virus] G1 to Compare the Efficacy, Safety, and Tolerability of Three Doses of Locteron [interferon alpha-2b] Plus Ribavirin Given Bi-Weekly in Comparison With PEG-Intron [peginterferon-alfa-2B] Plus Ribavirin Given Weekly.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Interferon alpha-2b (Primary) ; Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms EMPOWER; SELECT-2
  • Sponsors Biolex
  • Most Recent Events

    • 28 Jun 2012 Planned number of patients changed from 100 to 108 as reported by European Clinical Trials Database.
    • 10 May 2011 Results of a preliminary analysis of the sustained virological response rates presented at the Digestive Disease Week 2011.
    • 04 Apr 2011 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top